Cofttek holdings limited

HER2&FLT3

BPR1J-097 (1327167-19-0)

BPR1J-097 is a novel small molecule FLT-3 inhibitor(IC50=11±7 nM) with promising in vivo anti-tumour activities; inhibits FLT-3 D835Y with an IC50 of 3 nM..

Not Intended for Therapeutic Use. For research use only.

CAS: 1327167-19-0 Category

BPR1J-097 (1327167-19-0) Description:

BPR1J-097 is a novel small molecule FLT-3 inhibitor with promising in vivo anti-tumour activities. BPR1J-097 may be useful in AML treatments.IC50 of BPR1J-097 required to inhibit FLT3 kinase activity ranged from 1 to 10 nM, and the 50% growth inhibition concentrations (GC(50)s) were 21±7 and 46±14 nM for MOLM-13 and MV4-11 cells, respectively. BPR1J-097 inhibited FLT3/signal transducer and activator of transcription 5 phosphorylation and triggered apoptosis in FLT3-driven AML cells. BPR1J-097 also showed favourable pharmacokinetic property and pronounced dose-dependent tumour growth inhibition and regression in FLT3-driven AML murine xenograft models.

BPR1J-097 (1327167-19-0) Specifications:

Product Name BPR1J-097
Chemical Name Bpr1j-097; 1327167-19-0; CHEMBL1807392; N-[5-(3-benzenesulfonamidophenyl)-1H-pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide; BPR1J097; SCHEMBL12077294
Purity ≥98% (HPLC)
CAS Number 1327167-19-0
Molecular Formula C27H28N6O3S
Molecular Weight 516.62 g/mol
Monoisotopic Mass 516.194 g/mol
InChIKey RRKKHABFIOHAOI-UHFFFAOYSA-N
InChi Code InChI=1S/C27H28N6O3S/c1-32-14-16-33(17-15-32)23-12-10-20(11-13-23)27(34)28-26-19-25(29-30-26)21-6-5-7-22(18-21)31-37(35,36)24-8-3-2-4-9-24/h2-13,18-19,31H,14-17H2,1H3,(H2,28,29,30,34)
SMILES O=C(NC1=CC(C2=CC=CC(NS(=O)(C3=CC=CC=C3)=O)=C2)=NN1)C4=CC=C(N5CCN(C)CC5)C=C4
Form Powder
Color white
Solubility  Soluble in DMSO
Storage Temp.  -20°C
Shelf life >2 years if stored properly
Handling Protect from air and moisture
Application a novel small molecule FLT-3 inhibitor

 


=

RIDADR NONH for all modes of transport

References:

1: Lin WH, Jiaang WT, Chen CW, Yen KJ, Hsieh SY, Yen SC, Chen CP, Chang KY, Chang CY, Chang TY, Huang YL, Yeh TK, Chao YS, Chen CT, Hsu JT. BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br J Cancer. 2012 Jan 31;106(3):475-81. doi: 10.1038/bjc.2011.564. Epub 2011 Dec 20. PubMed PMID: 22187040; PubMed Central PMCID: PMC3273346.